Video

Dr. Czerniecki on Treatment Options for Patients With HER2+ Brain Metastases

Brian Czerniecki, MD, PhD, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.

Brian Czerniecki, MD, PhD, chair and senior member, Department of Breast Oncology at Moffitt Cancer Center, discusses treatment options for patients with HER2-positive breast cancer who have brain metastases.

Local or systemic HER2-directed therapies are critical in treating patients with brain metastases, says Czerniecki.

These agents may be delivered into the brain in the central nervous system (CNS) via CNS catheters such as the MAYA balloon catheter, explains Czerniecki. The MAYA catheter, placed in the patient’s cerebrospinal fluid, can deliver higher levels of the targeted agent across the blood–brain barrier compared with systemic therapy alone.

Additionally, TKIs including tucatinib (Tukysa), neratinib (Nerlynx), and lapatinib (Tykerb) have demonstrated some utility in patients with HER2-positive disease and brain metastases, says Czerniecki.

For example, lapatinib is a smaller molecule that can cross the blood–brain barrier. Tucatinib, which was recently granted FDA approval in metastatic HER2-positive breast cancer, has demonstrated CNS activity as well, concludes Czerniecki. 

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity